Patents by Inventor Anders Høgset
Anders Høgset has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115731Abstract: The present invention concerns an in vivo method for introducing a naked mRNA molecule into the cytosol of a cell(s) in a subject, by the use of photochemical internalization, wherein the photosensitising agent is a sulphonated meso-tetraphenyl chlorin, sulfonated tetraphenylporphine or a di- or tetrasulfonated aluminium phthalocyanine used in an amount of 0.000001-0.001 ?g and the cells(s) are contacted with the mRNA molecule and photosensitising agent for 30 seconds to 10 minutes before irradiation of the cell(s). The method may be used to express a polypeptide in the subject. The method is also directed to pharmaceutical compositions containing the photosensitising agents and the mRNA and uses of the molecules in therapy, e.g. to treat or prevent cancer or an infection.Type: ApplicationFiled: February 8, 2022Publication date: April 11, 2024Applicant: PCI Biotech ASInventor: Anders HØGSET
-
Patent number: 11648287Abstract: A method of treating or preventing an intracellular bacterial infection, comprising contacting the cell(s) which are infected with an antibacterial agent and a photosensitizing agent and irradiating the cell(s) with light of a wavelength effective to activate the photosensitizing agent, wherein the antibacterial agent is released into the cytosol of the cell(s) and kills, damages or prevents the replication of bacteria in said cell(s) is described. Related uses, and compositions, products and kits for the same are further described.Type: GrantFiled: November 9, 2018Date of Patent: May 16, 2023Assignees: ACADEMISCH MEDISCH CENTRUM, PCI BIOTECH ASInventors: Anders Høgset, Sebastian A. J. Zaat, Xiaolin Zhang
-
Patent number: 11027017Abstract: The invention concerns a method of generating an immune response in a subject, comprising administering to the subject an antigenic molecule, a photosensitizing agent, a checkpoint inhibitor, and irradiating said subject with light of a wavelength effective to activate the photosensitizing agent to generate an immune response. Preferably the method is a method of vaccination. The invention also provides related methods, compositions, cells, uses, products and kits.Type: GrantFiled: March 4, 2016Date of Patent: June 8, 2021Assignee: PCI Biotech ASInventor: Anders Høgset
-
Patent number: 10973896Abstract: The present invention relates to a method of treating or preventing melanoma using vaccination or immunisation, wherein said vaccination or immunisation involves the use of a photosensitizing agent, a melanoma antigen (i.e. an antigenic molecule), for example a vaccine component, and irradiation with light of a wavelength effective to activate the photosensitizing agent. The invention also relates to said photosensitizing agent and melanoma antigen for use in such a method, and to cells produced by the method.Type: GrantFiled: November 21, 2014Date of Patent: April 13, 2021Assignee: PCI Biotech ASInventors: Anders Høgset, Pål Johansen
-
Publication number: 20210052628Abstract: The present invention concerns an in vivo method for introducing an mRNA molecule (which is not associated with a carrier) into the cytosol of a cell(s) in a subject, by the use of photochemical internalization, wherein the photosensitising agent is a sulphonated meso-tetraphenyl chlorin, sulfonated tetraphenylporphine or a di- or tetrasulfonated aluminium phthalocyanine used in an amount of 0.0001 to 1 ?g. The method may be used to express a polypeptide in the subject. The invention is also directed to pharmaceutical compositions containing the photosensitising agents and the mRNA and uses of the molecules in therapy, e.g. to treat or prevent cancer or an infection.Type: ApplicationFiled: January 24, 2019Publication date: February 25, 2021Applicant: PCI Biotech ASInventor: Anders HØGSET
-
Publication number: 20200338044Abstract: The present invention provides a method of treating a cholangiocarcinoma in a human patient comprising a photochemical internalization method using TPCS2a, and gemcitabine and optionally another cytotoxic agent, preferably cisplatin. Related uses and kit for performing the invention are also provided.Type: ApplicationFiled: October 13, 2017Publication date: October 29, 2020Applicant: PCI Biotech ASInventors: Anders HØGSET, Per Edvard WALDAY, Pål Kristian SELBO, Kristin EIVINDVIK, Lena FINNESAND
-
Publication number: 20200268834Abstract: The present invention provides a method of treating or preventing an intracellular bacterial infection, comprising contacting the cell(s) which are infected with an antibacterial agent and a photosensitizing agent and irradiating the cell(s) with light of a wavelength effective to activate the photosensitizing agent, wherein the antibacterial agent is released into the cytosol of the cell(s) and kills, damages or prevents the replication of bacteria in said cell(s). The invention also provides related uses, and compositions, products and kits for the same.Type: ApplicationFiled: November 9, 2018Publication date: August 27, 2020Applicants: PCI Biotech AS, Academisch Medisch CentrumInventors: Anders HØGSET, Sebastian A.J. ZAAT, Xiaolin ZHANG
-
Patent number: 10537639Abstract: The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of a cell using a photochemical internalization method in which a cytokine, preferably GM-CSF, is used to enhance the method. The method may be used to stimulate an immune response and for various therapeutic or prophylactic methods. Pharmaceutical compositions or kits comprising the components for use in the method, cells produced by the method and their use in therapy and prophylaxis also form aspects of the invention.Type: GrantFiled: August 28, 2015Date of Patent: January 21, 2020Assignee: PCI BIOTECH ASInventors: Anders Høgset, Pål Johansen
-
Publication number: 20180050105Abstract: The invention concerns a method of generating an immune response in a subject, comprising administering to the subject an antigenic molecule, a photosensitizing agent, a checkpoint inhibitor, and irradiating said subject with light of a wavelength effective to activate the photosensitizing agent to generate an immune response. Preferably the method is a method of vaccination. The invention also provides related methods, compositions, cells, uses, products and kits.Type: ApplicationFiled: March 4, 2016Publication date: February 22, 2018Applicant: PCI Biotech ASInventor: Anders HØGSET
-
Publication number: 20170252441Abstract: The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of a cell using a photochemical internalisation method in which a cytokine, preferably GM-CSF, is used to enhance the method. The method may be used to stimulate an immune response and for various therapeutic or prophylactic methods. Pharmaceutical compositions or kits comprising the components for use in the method, cells produced by the method and their use in therapy and prophylaxis also form aspects of the invention.Type: ApplicationFiled: August 28, 2015Publication date: September 7, 2017Applicant: PCI Biotech ASInventors: Anders HØGSET, Pål JOHANSEN
-
Publication number: 20170143811Abstract: The present invention relates to a method of treating or preventing melanoma using vaccination or immunisation, wherein said vaccination or immunisation involves the use of a photosensitizing agent, a melanoma antigen (i.e. an antigenic molecule), for example a vaccine component, and irradiation with light of a wavelength effective to activate the photosensitizing agent. The invention also relates to said photosensitizing agent and melanoma antigen for use in such a method, and to cells produced by the method.Type: ApplicationFiled: November 21, 2014Publication date: May 25, 2017Applicant: PCI Biotech ASInventors: Anders HØGSET, Pål JOHANSEN
-
Publication number: 20160040128Abstract: The present invention provides an in vitro method of expressing an antigenic molecule or a part thereof on the surface of a dendritic cell using a PCI method with TPCS2a at a concentration of 0.020-0.1 ?g/ml, using light of a wavelength of between 400 and 500 nm. Methods of treatment such as vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.Type: ApplicationFiled: March 15, 2013Publication date: February 11, 2016Applicant: PCI BIOTECH ASInventors: Pål JOHANSEN, Anders HØGSET
-
Patent number: 9241996Abstract: The present invention relates to a method for enhancing the activity of kinase inhibitors in target cells, and more specifically for enhancing the activity of tyrosine kinase inhibitors (TKIs), said method comprising contacting a cell with a kinase inhibitor and a photosensitizing agent and irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, and to the use of this method for enhancing the effects of kinase inhibitors or kinase inhibitor-based drugs in particular to achieve cell death, for example, in cancer treatment and other diseases or conditions in which kinase inhibitors, such as TKIs, have a beneficial effect.Type: GrantFiled: June 26, 2009Date of Patent: January 26, 2016Assignee: PCI BIOTECH ASInventors: Anders Høgset, Anette Weyergang, P{dot over (a)}l Kristian Selbo, Kristian Berg
-
Publication number: 20110293575Abstract: The present invention relates to a method for enhancing the activity of kinase inhibitors in target cells, and more specifically for enhancing the activity of tyrosine kinase inhibitors (TKIs), said method comprising contacting a cell with a kinase inhibitor and a photosensitizing agent and irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, and to the use of this method for enhancing the effects of kinase inhibitors or kinase inhibitor-based drugs in particular to achieve cell death, for example, in cancer treatment and other diseases or conditions in which kinase inhibitors, such as TKIs, have a beneficial effect.Type: ApplicationFiled: June 26, 2009Publication date: December 1, 2011Applicant: PCI BIOTECH ASInventors: Anders Høgset, Anette Weyergang, Pål Kristian Selbo, Kristian Berg
-
Patent number: 7521239Abstract: A method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitizing agent, the cell is irradiated with light of a wavelength effective to activate the photosensitizing agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.Type: GrantFiled: November 29, 2001Date of Patent: April 21, 2009Assignee: PCI Biotech ASInventors: Anders Høgset, Kristian Berg, Gunhild Mari Mælandsmo, Birgit Øvstebø Engesæter, Lina Prasmickaite
-
Patent number: 7223600Abstract: The present invention provides a method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosentistising agent, the cell is irradiated with light of a wavelength effective to activate the photosentisitising agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.Type: GrantFiled: November 29, 2001Date of Patent: May 29, 2007Assignee: The Norwegian Radium Hospital Research FoundationInventors: Kristian Berg, Lina Prasmickaite, Anders Høgset, Pål Kristian Selbo
-
Patent number: 6680301Abstract: The present invention relates to a method for introducing molecules in cells by disrupting endosomal and lysosomal membranes using photodynamic treatment, without killing the majority of the cells by the photodynamic treatment. More particularly, this invention includes a method for transferring DNA and/or RNA, such as genes, to cells by photochemically inducing the disruption of endosomes and lysosomes.Type: GrantFiled: September 1, 1998Date of Patent: January 20, 2004Assignee: Photocure ASInventors: Kristian Berg, Kirsten Sandvik, Johan Moan, Anders Høgset
-
Patent number: 6680047Abstract: Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.Type: GrantFiled: August 10, 2001Date of Patent: January 20, 2004Assignee: Amersham Health ASInventors: Jo Klaveness, Pål Rongved, Anders Høgset, Helge Tolleshaug, Alan Cuthbertson, Aslak Godal, Lars Hoff, Geir Gogstad, Klaus Bryn, Anne Nævestad, Dagfinn Løvhaug, Halldis Hellebust, Magne Solbakken
-
Patent number: 6331289Abstract: Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.Type: GrantFiled: October 28, 1997Date of Patent: December 18, 2001Assignee: Nycomed Imaging ASInventors: Jo Klaveness, Pål Rongved, Anders Høgset, Helge Tolleshaug, Alan Cuthbertson, Lars Hoff, Klaus Bryn, Halldis Hellebust, Magne Solbakken
-
Patent number: 6261537Abstract: Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilised by monolayers of film-forming surfactants, the reporter being coupled or linked to at least one vector.Type: GrantFiled: October 29, 1997Date of Patent: July 17, 2001Assignee: Nycomed Imaging ASInventors: Jo Klaveness, Pål Rongved, Anders Høgset, Helge Tolleshaug, Anne Nævestad, Halldis Hellebust, Lars Hoff, Alan Cuthbertson, Dagfinn Løvhaug, Magne Solbakken